J 2024

Acetylsalicylic acid use and development of cardiac allograft vasculopathy: A national prospective study using highly automated 3-D optical coherence tomography analysis

MAYEROVA, Lucie, Peter WOHLFAHRT, Milan SONKA, Zhi CHEN, Josef KAUTZNER et. al.

Základní údaje

Originální název

Acetylsalicylic acid use and development of cardiac allograft vasculopathy: A national prospective study using highly automated 3-D optical coherence tomography analysis

Autoři

MAYEROVA, Lucie (203 Česká republika), Peter WOHLFAHRT (203 Česká republika), Milan SONKA (203 Česká republika), Zhi CHEN, Josef KAUTZNER (203 Česká republika), Vojtech MELENOVSKY (203 Česká republika), Vladimir KARMAZIN (203 Česká republika), Ivan MALEK (203 Česká republika), Helena BEDANOVA (203 Česká republika), Ales TOMASEK (203 Česká republika), Eva OZÁBALOVÁ (203 Česká republika, domácí), Jan KREJČÍ (203 Česká republika, domácí), Tomas KOVARNIK (203 Česká republika) a Michal PAZDERNIK (203 Česká republika)

Vydání

CLINICAL TRANSPLANTATION, HOBOKEN, WILEY, 2024, 0902-0063

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.100 v roce 2022

Organizační jednotka

Lékařská fakulta

UT WoS

001183729600001

Klíčová slova anglicky

acetylsalicylic acid; cardiac allograft vasculopathy; lipid plaque; OCT

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 10. 6. 2024 13:29, Mgr. Tereza Miškechová

Anotace

V originále

BackgroundThere is conflicting evidence on the role of acetylsalicylic acid (ASA) use in the development of cardiac allograft vasculopathy (CAV).MethodsA nationwide prospective two-center study investigated changes in the coronary artery vasculature by highly automated 3-D optical coherence tomography (OCT) analysis at 1 month and 12 months after heart transplant (HTx). The influence of ASA use on coronary artery microvascular changes was analyzed in the overall study cohort and after propensity score matching for selected clinical CAV risk factors.ResultsIn total, 175 patients (mean age 52 +/- 12 years, 79% male) were recruited. During the 1-year follow-up, both intimal and media thickness progressed, with ASA having no effect on its progression. However, detailed OCT analysis revealed that ASA use was associated with a lower increase in lipid plaque (LP) burden (p = .013), while it did not affect the other observed pathologies. Propensity score matching of 120 patients (60 patient pairs) showed similar results, with ASA use associated with lower progression of LPs (p = .002), while having no impact on layered fibrotic plaque (p = .224), calcification (p = .231), macrophage infiltration (p = .197), or the absolute coronary artery risk score (p = .277). According to Kaplan-Meier analysis, ASA use was not associated with a significant difference in survival (p = .699)ConclusionThis study showed a benefit of early ASA use after HTx on LP progression. However, ASA use did not have any impact on the progression of other OCT-observed pathologies or long-term survival.